Study of APR-1051 in Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: APR-1051
Treatment-related adverse events, * Part 1 dose escalation: Incidence of adverse Events (AE), serious AEs (SAE), treatment-related AEs, AEs that would qualify as a dose-limiting toxicity (DLT), changes in clinical laboratory values, vital signs, ECG, ECHO
* Part 1 dose escalation: Severity of adverse Events (AE), serious AEs (SAE), treatment-related AEs, and changes in clinical laboratory values, vital signs, ECG, ECHO according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0, Day 1 to 28, each cycle is 28 days|Recommended dose of APR-1051, â€¢Part 1 dose escalation: Recommended Phase 2 Dose (RP2D) of APR-1051 monotherapy \[Time frame: Day 1 through to start of dose expansion phase\]. The RP2D of will be determined based on review of safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy data, Day 1 to 28, each cycle is 28 days
Pharmacokinetics: Cmax/Cmin of APR-1051, Plasma concentration of APR-1051: maximum (Cmax), minimum (Cmin), Day 1 to 112|Pharmacokinetics: Tmax of APR-1051, Time to peak plasma concentration of APR-1051 (Tmax), Day 1 to 112|Pharmacokinetics: AUC of APR-1051, Area under plasma versus time curve (AUC) of APR-1051 max), Day 1 to 112|Pharmacokinetics: t1/2 of APR-1051, Half-life of APR-1051 (t1/2), Day 1 to 112
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.